<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434704</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004423-78</org_study_id>
    <nct_id>NCT03434704</nct_id>
  </id_info>
  <brief_title>Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole</brief_title>
  <acronym>SIR-POSA</acronym>
  <official_title>A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis With Posaconazole.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciceri Fabio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SIR-POSA is a phase II trial of peripheral blood stem cell (PBSC) transplantation from a
      partially compatible family (Haplo) donor in patients with a blood tumor (myelodysplastic
      syndrome (MDS) and acute leukemia) treated for the prevention of primary fungal infections
      with posaconazole.

      The aim is evaluate the composite end-point graft-versus-host disease-free, relapse-free
      survival (GRFS) in these patients and evaluate the feasibility and efficacy of posaconazole
      oral tablets as primary antifungal prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft-versus-host disease-free, relapse-free survival (GRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>GRFS events is defined as the first event among grade III-IV acute Graft vs. Host Disease (GVHD), severe chronic GVHD, relapse and death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of antifungal prophylaxis strategy</measure>
    <time_frame>85 days after transplantation</time_frame>
    <description>The rate of proven, probable and possible invasive fungal diseases documented within the first 85 days after transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Transplant-Related Hematologic Malignancy</condition>
  <condition>Leukemia, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Graft Vs Host Disease</condition>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Single Arm Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning treatment &quot;Thiotepa-Treosulfan-Fludarabine&quot;; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conditioning treatment &quot;Thiotepa-Treosulfan-Fludarabine&quot;</intervention_name>
    <description>Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age &gt; 65 years.</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
    <other_name>TTF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PBSC graft</intervention_name>
    <description>(target 4-8 Ã— 106 CD34+ cells/kg patient body weight)</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GvHD prophylaxis</intervention_name>
    <description>Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.
Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: &gt;80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5.</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primary antifungal prophylaxis</intervention_name>
    <description>Posaconazole delayed-release tablet [available in 100 mg tablets]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.</description>
    <arm_group_label>Single Arm Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of myelodysplastic syndromes or acute leukemia

          -  Activation of an alternative donor search by the Italian Bone Marrow Donor Registry
             (IBMDR) with absence of a 10/10 Human Leukocyte Antigens (HLA) matched unrelated donor

          -  Age &gt;18

          -  Unavailability of a HLA-matched related donor (MRD)

          -  Performance status : Eastern Cooperative Oncology Group (ECOG) &lt;3

          -  Written and signed informed consent

          -  Life expectancy not severely limited by concomitant illness.

        Exclusion Criteria:

          -  Women of child-bearing potential who do not agree to abstinence or, if sexually
             active, do not agree to the use of highly effective method of birth control such as
             condoms, implants, injectables, combined oral contraceptives, intrauterine devices
             (IUDs), vasectomised partner on treatment and for at least 6 months thereafter.

          -  Pregnant or nursing (lactating) women.

          -  Known allergies, hypersensitivity, or intolerance to any experimental drugs.

          -  Any active, uncontrolled infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabio Ciceri, MD</last_name>
    <phone>0039022643</phone>
    <phone_ext>4289</phone_ext>
    <email>ciceri.clinicaltrials@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, MD</last_name>
      <phone>0039022643</phone>
      <phone_ext>4289</phone_ext>
      <email>ciceri.clinicaltrials@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Raffaella Greco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacopo Peccatori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Teresa Lupo Stanghellini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Assanelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Consuelo Corti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Ciceri Fabio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

